Infections Caused by Extended-Spectrum β-Lactamase Producing Escherichia Coli in Systemic Lupus Erythematosus Patients: Prevalence, Risk Factors, and Predictive Model
Table 3
(a) Demographics and clinical characteristics of SLE patients infected by E. coli
Characteristics
ESBL (+)
ESBL (-)
P value
(n, % / mean±SD)
n=212
n=172
Age,yrs
49.5±8.2
47.9±9.8
0.098
Female gender
206 (97.2)
163 (94.8)
0.227
ICU stay during hospitalization
35 (16.5)
11 (6.4)
0.002
Long of hospital stay, days
11.3±4.2
10.5±5.6
0.111
Hospitalization ≥ 48 hours in preceding 90 days
40 (18.9)
33 (19.2)
0.937
Enterobacteriaceae colonization or infection in preceding year
37 (17.5)
6 (3.5)
<0.001
Mechanical ventilation ≥ 48 hours
19 (8.9)
6 (3.5)
0.031
Deep vein catheter ≥ 48 hours
29 (13.7)
18 (10.5)
0.339
Urethral catheter≥ 48 hours
27 (12.7)
8 (4.7)
0.006
Residence of nursing home
33 (15.7)
11 (6.4)
0.005
Nosocomial acquired infection
41 (19.3)
18 (10.5)
0.026
Mortality
27 (12.7)
9 (5.2)
0.012
ESBL, Extended-Spectrum -Lactamase; ICU, intensive care unit.
(b) SLE status of the patients infected by E. coli
Characteristic (n)
ESBL (+)
ESBL (-)
P value
(n, % / mean±SD)
n=212
n=172
SLE activity at the time of infection
Lupus nephritis
42 (19.8)
32 (18.6)
0.766
Hematological activity
24 (11.3)
9 (5.2)
0.034
Central nervous system activity
7 (3.3)
3 (1.7)
0.341
Course of SLE, month
42.5±11.3
40.2±14.7
0.084
Immunosuppressive treatment
45 (21.2)
25 (14.5)
0.058
Daily prednisone dose at the time of infection, mg
